HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series

Background: Patients with gastric cancer (GC) have a poor survival and biologicals such as Trastuzumab have not been used routinely in these patients. Existing data on HER2 expression and its clinical relevance in GC are still limited and controversial. Methods: HER2 expression was investigated by i...

Descripción completa

Detalles Bibliográficos
Autores principales: Grabsch, Heike, Sivakumar, Shivan, Gray, Sally, Gabbert, Helmut E., Müller, Wolfram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2010
Materias:
Other
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619246/
https://www.ncbi.nlm.nih.gov/pubmed/20208134
http://dx.doi.org/10.3233/CLO-2009-0497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619246/
https://www.ncbi.nlm.nih.gov/pubmed/20208134
http://dx.doi.org/10.3233/CLO-2009-0497

Ejemplares similares